Johnson and Johnson

9 oct. 2026, 23:50 UTC

Johnson & Johnson announced new two-year results from the Phase 3 ICONIC-LEADa study for ICOTYDE® in treating moderate-to-severe plaque psoriasis.

8 oct. 2026, 23:05 UTC

Johnson & Johnson shares declined in after-market hours, remaining below their 20-day moving average and near the lower end of their one-month range.

7 oct. 2026, 20:01 UTC

Guggenheim reiterated its Buy rating on Johnson & Johnson with a $287 price target as the stock advances, having gained momentum since Tuesday's close.

6 oct. 2026, 20:07 UTC

RBC Capital maintained its Outperform rating on Johnson & Johnson and raised its price target to $290, contributing to a modest increase in shares today.

5 oct. 2026, 19:52 UTC

Johnson & Johnson shares fell sharply despite Citi raising its price target to $303 ahead of next week's earnings report, continuing a trend of lower performance.

2 oct. 2026, 20:07 UTC

Johnson & Johnson shares declined as the company presented positive data from its ICONIC-TOTAL study, showing 70% of patients achieved clear skin at Week 112.

1 oct. 2026, 23:05 UTC

Johnson & Johnson is trading slightly higher in after-market hours, recovering from three consecutive lower daily closes, though still below its 20-day moving average.

30 sept. 2026, 23:01 UTC

Johnson & Johnson's shares rose in after-market trading, buoyed by stronger-than-expected GDP growth of 2.2% for Q2, revised from 1.5%.

29 sept. 2026, 20:01 UTC

Johnson & Johnson's shares fell sharply as Bank of America Securities projects Q3 earnings below consensus, with a price target raised to $278.

28 sept. 2026, 20:07 UTC

Johnson & Johnson shares are higher following positive long-term efficacy results for its CAR T therapy, Carvykti, presented at the International Myeloma Society congress.

26 sept. 2026, 00:01 UTC

Johnson & Johnson's TREMFYA® met endpoints in the Phase 4 STAR study, but the stock is trading lower in after-market hours amid routine fluctuations.

25 sept. 2026, 20:07 UTC

Johnson & Johnson's stock rose after positive Phase 4 STAR study results for Tremfya and encouraging long-term data for CARVYKTI in multiple myeloma patients.

24 sept. 2026, 23:01 UTC

Johnson & Johnson's shares are advancing in after-market trading, holding a roughly flat position since Thursday's close amid limited fluctuations.

23 sept. 2026, 23:05 UTC

Johnson & Johnson is experiencing a slight decline in after-market trading, reflecting a cumulative return near the lower end of its one-month trading range.

22 sept. 2026, 20:07 UTC

Johnson & Johnson shares fell following a slight decline from Monday's close, despite bullish social media sentiment and positive Phase 3 study results for CAPLYTA®.

21 sept. 2026, 20:06 UTC

Johnson & Johnson's stock is declining today despite receiving EU approval for ICOTYDE, a new treatment for plaque psoriasis, and positive Phase 3 results for Caplyta.

18 sept. 2026, 23:01 UTC

Johnson & Johnson's shares advanced modestly in after-market trading, continuing positive momentum following five consecutive sessions that ended higher.

17 sept. 2026, 23:06 UTC

Johnson & Johnson is trading slightly higher in after-market hours, continuing a trend of five consecutive sessions finishing higher since Thursday's close.

16 sept. 2026, 23:06 UTC

Johnson & Johnson's shares are trading lower in after-market hours, briefly dipping to a low while remaining below their 20-day moving average.

15 sept. 2026, 23:01 UTC

Johnson & Johnson shares are lower in after-market trading amid negative market sentiment following a sharp decline in the New York Empire State Manufacturing Index.

14 sept. 2026, 23:06 UTC

Johnson & Johnson shares rose in after-market trading following the final survival analysis results of the Phase 3 PAPILLON study for RYBREVANT and chemotherapy.

12 sept. 2026, 00:01 UTC

Johnson & Johnson shares rose in after-hours trading amid reports of Apollo Global Management discussing a $20 billion acquisition of its DePuy Synthes unit.

11 sept. 2026, 23:41 UTC

Johnson & Johnson shares higher after news of Apollo Global Management's interest in acquiring its $20 billion orthopedics unit, DePuy Synthes.

10 sept. 2026, 20:07 UTC

Johnson & Johnson shares are lower despite receiving CE Marking for its ACUVUE OASYS MAX 2-Week lens, with HSBC raising its price target to $320.

9 sept. 2026, 23:01 UTC

Johnson & Johnson shares are higher in after-market trading, reflecting a modest increase since Wednesday's close despite three consecutive sessions of declines.

8 sept. 2026, 20:02 UTC

Johnson & Johnson shares are lower today amid declines in the Pharmaceuticals sub-sector, despite strong merger and acquisition capacity estimated at $80 billion.

5 sept. 2026, 00:01 UTC

Johnson & Johnson shares are higher in after-market trading, with no specific news driving the move. The stock reached a session high earlier today.

4 sept. 2026, 20:08 UTC

Shares of Johnson & Johnson are lower as Timothy Schmid exercised stock options for 33,597 shares valued at approximately $4.39 million.

3 sept. 2026, 23:41 UTC

Johnson & Johnson's shares are lower in after-market trading following FDA approval of IMAAVY and a jury verdict in a talc case.

2 sept. 2026, 23:06 UTC

Johnson & Johnson will participate in the Deutsche Bank 2026 Healthcare Summit on September 17. Shares are higher in after-market trading following the announcement.